Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Does India's Perpetual Licensing Plan Risk Backfiring?

Executive Summary

India's wide-ranging drug regulation overhaul plan, including a perpetual licensing system aimed at simplifying processes and potentially delinking licensing and enforcement responsibilities may well emerge as a double-edged sword.

You may also be interested in...

India Drug Watchdog Says 4-5% Of Drugs Still Substandard

Health authorities have been working for years toward ensuring the safety of medicines in the global supply chain, and India - one of the biggest providers of inexpensive generics worldwide - has been a key focus. But while the incidence of substandard medicines in the country has fallen, it still hovers at around 4-5% of supplies, according to the country’s drug regulator, which is proposing new steps.

India's Proposed Tweak Of New Drug Rules: Bridge To Data Exclusivity?

A key Indian advisory panel is expected to consider a crucial tweak to certain regulations pertaining to the approval of “new drugs”, which domestic firms allege could facilitate a different form of data exclusivity and also limit competition.

Abbott Defines Bullishness On India

The 50th annual general meeting of the Organization of Pharmaceutical Producers of India (OPPI) in Mumbai saw an eclectic mix of leaders from academia, politics, bureaucracy and industry in full attendance. Abbott's bullishness on the Indian market and suggestions for concerted efforts to move the access needle were among the key takeaways of the event.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts